Review decision on sNDA for Actelion’s Tracleer awaits finalized REMS
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Actelion must finalize the Risk Evaluation and Mitigation Strategy for Tracleer (bosentan) before FDA will finish reviewing its sNDA for less severe pulmonary arterial hypertension, according to an agency "complete response" letter announced March 2. Actelion submitted a REMS proposal in September 2008, but FDA is now delaying action on the expanded indication until the REMS is finalized and approved by the agency. Tracleer has been marketed since 2001 for patients with moderate to severe PAH with a risk management plan to manage the associated safety concerns of potential for serious liver injury and damage to fetuses. When FDA gained the REMS authority under the FDA Amendments Act last March, it included Tracleer among the marketed drugs with existing risk management plans that needed to turn those plans into REMS
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.